132 Clario, a software provider for drugmakers, has reportedly filed confidentially for an initial public offering (IPO) in the United States, targeting a valuation of more than $10 billion. This move comes as the U.S. IPO market shows signs of revival in 2024, following a period of sluggish activity, buoyed by optimistic economic conditions. According to Bloomberg News, Clario is collaborating with underwriters JPMorgan Chase & Co., Morgan Stanley, Jefferies Financial Group, and UBS Group AG for its IPO process. The information is based on sources familiar with the matter, as Clario has not yet responded to requests for comment from Reuters. If successful, Clario’s IPO could represent a significant milestone for the company, positioning it to capitalize on investor interest in healthcare and pharmaceutical software solutions. You Might Be Interested In Meta Enhances AI Image Generation for Ads Intuit and The Farmlink Project: Fighting Food Waste and Climate Change Alphabet and Microsoft Earnings Highlight Significant AI Investments Driving Growth Ford Motor Adjusts DEI Program Amidst Growing Pressure from Conservative Groups Sanlam Achieves Record Earnings, Foresees Long-Term Growth Amid Short-Term Challenges UnitedHealth Predicts Greater Impact on Annual Earnings Due to February Hack but Maintains Full-Year Profit Forecast
